BRPI0901602B8 - formulação farmacêuticas - Google Patents

formulação farmacêuticas

Info

Publication number
BRPI0901602B8
BRPI0901602B8 BRPI0901602A BRPI0901602A BRPI0901602B8 BR PI0901602 B8 BRPI0901602 B8 BR PI0901602B8 BR PI0901602 A BRPI0901602 A BR PI0901602A BR PI0901602 A BRPI0901602 A BR PI0901602A BR PI0901602 B8 BRPI0901602 B8 BR PI0901602B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
composition
free
formulation
present
Prior art date
Application number
BRPI0901602A
Other languages
English (en)
Inventor
Giuliana Tinti Flavia
Vian Marques Ricardo
Matha Vladimir
Original Assignee
Ems S/A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ems S/A filed Critical Ems S/A
Priority to BRPI0901602A priority Critical patent/BRPI0901602B8/pt
Priority to PCT/BR2010/000097 priority patent/WO2010111759A1/pt
Priority to EP10757955.9A priority patent/EP2415465A4/en
Publication of BRPI0901602A2 publication Critical patent/BRPI0901602A2/pt
Priority to US13/251,884 priority patent/US20120077872A1/en
Publication of BRPI0901602B1 publication Critical patent/BRPI0901602B1/pt
Publication of BRPI0901602B8 publication Critical patent/BRPI0901602B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composições farmaceuticas de tetrahidrolipstatina livres de estabilizantes a presente invenção refere-se a uma composição e a uma formulação farmacêutica que compreende a mistura de uma quantidade efetiva de pós ou grânulos de um composto derivado de leucina e pelo menos uma substância excipiente farmaceuticamente aceitável utilizada como carreador. particularmente a principal característica da formulação e composição ora objetos da presente invenção consiste no fato das mesmas serem livre de agentes estabilizantes e poderem ser formuladas em qualquer formulação farmacêutica oral convencional.
BRPI0901602A 2009-04-03 2009-04-03 formulação farmacêuticas BRPI0901602B8 (pt)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0901602A BRPI0901602B8 (pt) 2009-04-03 2009-04-03 formulação farmacêuticas
PCT/BR2010/000097 WO2010111759A1 (pt) 2009-04-03 2010-04-01 Composições farmacêuticas de tetrahidrolipstatina livres de estabilizantes
EP10757955.9A EP2415465A4 (en) 2009-04-03 2010-04-01 STABILIZATION-FREE PHARMACEUTICAL TETRAHYDROLIPSTATINE COMPOSITIONS
US13/251,884 US20120077872A1 (en) 2009-04-03 2011-10-03 Preservative-free pharmaceutical tetrahydrolipstatin compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0901602A BRPI0901602B8 (pt) 2009-04-03 2009-04-03 formulação farmacêuticas

Publications (3)

Publication Number Publication Date
BRPI0901602A2 BRPI0901602A2 (pt) 2010-12-21
BRPI0901602B1 BRPI0901602B1 (pt) 2019-07-02
BRPI0901602B8 true BRPI0901602B8 (pt) 2021-05-25

Family

ID=42827430

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0901602A BRPI0901602B8 (pt) 2009-04-03 2009-04-03 formulação farmacêuticas

Country Status (4)

Country Link
US (1) US20120077872A1 (pt)
EP (1) EP2415465A4 (pt)
BR (1) BRPI0901602B8 (pt)
WO (1) WO2010111759A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
EP1470116A4 (en) * 2001-12-04 2005-04-06 Biogal Gyogyszergyar PREPARATION OF THE ORLISTAT AND CRYSTALLINE FORMS OF THE ORLISTAT
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
KR100625399B1 (ko) * 2002-04-26 2006-09-20 에프. 호프만-라 로슈 아게 리파아제 억제제 및 글루코마난을 포함하는 약학 조성물
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
ES2350798T3 (es) * 2007-09-12 2011-01-27 Mader S.R.L. Composiciones farmacéuticas para uso oral para tratar a pacientes afectados por la obesidad.
EA201070378A1 (ru) * 2007-09-17 2010-08-30 Др. Редди`С Лабораторис Лтд. Фармацевтические составы орлистата
PL216542B1 (pl) * 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku

Also Published As

Publication number Publication date
WO2010111759A1 (pt) 2010-10-07
BRPI0901602A2 (pt) 2010-12-21
EP2415465A4 (en) 2013-09-11
US20120077872A1 (en) 2012-03-29
BRPI0901602B1 (pt) 2019-07-02
EP2415465A1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CY1116698T1 (el) Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BR112013005679A2 (pt) imidazopiridazinas substituídas
MX2013003365A (es) Composicion farmaceutica.
BR112012019997A2 (pt) composições de cuidado oral
DK2004168T3 (da) Stabil oral farmaceutisk sammensætning indeholdende thyroidhormonreceptoragonister
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
EP2528578A4 (en) DENTAL COMPOSITION USING A CALCIUM SOURCE
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
BR112012032882A2 (pt) liberação aumentada de ingredientes lopofílicos de goma de mascar com hidrocoloides
BR112015029468A2 (pt) sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
PE20140702A1 (es) Composiciones que comprenden un inhibidor de pi3k y un inhibidor de mek
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
CR20190298A (es) Amidas aromáticas de ácido carboxílico
TR201004464A2 (tr) Kemik erimesi için formülasyon.
PE20142460A1 (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel
MX2015009348A (es) Composiciones hemostaticas.
BR112015028302A2 (pt) formulação de pastilha de nicotina
BRPI0901602B8 (pt) formulação farmacêuticas

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B25M Limitations in changing the proprietorship

Free format text: ANOTADO O ARROLAMENTO DO PEDIDO DE PATENTE, CONFORME DETERMINACAO DA DELEGACIA DA RECEITA FEDERAL DO BRASIL EM CAMPINAS.

B25G Requested change of headquarter approved

Owner name: EMS S/A (BR/SP)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110039790/RJ DE 20/04/2011.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF